Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020 Global Report Featuring 20 Companies & Respective Devices - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

The Electroencephelographs (EEG) - Pipeline Insight and Competitive Landscape, 2020, report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape.

Growing prevalence of neurological diseases and increasing awareness about these are significant contributing factors to advancement. Hence, the market is expected to growth in the coming years. The industries invest in R&D to upgrade existing products and create new ones to satisfy the rising demand for specialized equipment, which is the major reason for an extensive pipeline in this segment. This report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices.

Electroencephelographs Devices Competitive Assessment

This segment of the Electroencephelographs report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development.

Product Type

Electroencephelographs can divided based on Types - Standalone devices and Portable devices- both are covered in this report.

• Product Channels

Electroencephelographs can be divided based on Channels - 8-channel EEG, 21-channel EEG, 25 channel EEG, 32-channel EEG, 40-channel EEG, Multi-channel EEG.

Major Players in Electroencephelographs

There are approx. 20+ key companies which are developing the products for Electroencephelographs.

Cerora Borealis: Cerora

The Cerora Borealis medical device platform is subject to FDA review and designed to measure and record brainwave activity (EEG) as well as other biosensor data, including cognitive data and voice-based data streams. The platform provides state of the art, mobile and versatile multimodal biosensor data. The first release is intended as an adjunct to standard clinical practice to aid in the evaluation of subject's medical or psychological state. Cerora's next generation devices are intended to aid in the diagnosis and management of various brain disorders, injuries, and diseases. The first release of Borealis is estimated to ship into US markets in 2021 at the earliest.

Circaid EEG: Circadian Therapeutics

Circaid EEG is being developed by Circadian Therapeutics. Its proof of concept study has already being done and prototype dev phase is ongoing. In a controlled clinical evaluation, data obtained using Circaid EEG correlate highly with those derived from traditional PSG recording equipment. Work continues towards CE marking and US 510(k) approval.

Electroencephelographs (EEG) Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

• Brand Positioning of Leading companies
• Application
• Industry Collaborations

Electroencephelographs (EEG): Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of EEG devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

• In June 2020 a study investigating EEG microstate dynamics in schizophrenia was the first research on the temporal structure of the four canonical EEG microstates of schizophrenic patient siblings. Results indicate that a possible endophenotype for schizophrenia is the dynamics of resting-state EEG microstats, specifically classes C and D.
• In April 2020, Marking a major milestone on the path to meeting the objectives of the NIH BRAIN initiative, researchers developed advanced high-density electroencephalography (EEG) as the future paradigm for dynamic functional neuroimaging. The study also marks one of the first times high-density EEG has been used to study epileptic seizures. The more powerful imaging technology, packing more than double the electrodes generally used in a clinical setting, is now available to patients treated at the Mayo Clinic.

Further commercial activities are provided in the report..

Electroencephelographs (EEG): Reimbursement

FDA approval alone is not a basis for coverage. Electroencephalographic (EEG) monitoring and video recording is a procedure and therefore is not regulated by the FDA. Medicare does not have a National Coverage Determination (NCD) for electroencephalographic (EEG) monitoring and video recording. Local Coverage Determinations (LCDs) exist.

Key Players

• AAT Medical Ltd
• Advanced Medical Electronics Corp
• Advanced neurometrics inc.
• Belluscura Limited
• BioSignal Analytics Inc
• Bio-Signal Group Corp.
• Bittium Biosignals Ltd
• BrainCare OY'
• BrainScope Company Inc
• Cerora Inc
• Circadian Therapeutics
• Cognionics, Inc.
• Cogwear LLC
• Compumedics Ltd
• Electrical Geodesics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5yhktr